StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of NASDAQ EVOK opened at $0.46 on Friday. The stock’s 50-day simple moving average is $0.59 and its two-hundred day simple moving average is $0.90. Evoke Pharma has a twelve month low of $0.42 and a twelve month high of $2.40.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter. The business had revenue of $1.68 million during the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- Election Stocks: How Elections Affect the Stock Market
- 3 Stocks Leading the U.S. Agriculture Comeback
- 5 discounted opportunities for dividend growth investors
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
